FAQs on the FDA Approval of Sarclisa SC (isatuximab-irfc) for Myeloma Indications Read more about FAQs on the FDA Approval of Sarclisa SC (isatuximab-irfc) for Myeloma IndicationsAdd new comment
Landmark ECOG-ACRIN ENDURANCE Study Co-Authored by International Myeloma Foundation Leaders Provides Evidence for Optimal Duration of Maintenance Therapy Read more about Landmark ECOG-ACRIN ENDURANCE Study Co-Authored by International Myeloma Foundation Leaders Provides Evidence for Optimal Duration of Maintenance TherapyAdd new comment
FDA Accepts New Drug Application for Mezigdomide in Combination with Carfilzomib and Dexamethasone as Treatment for Relapsed/Refractory Myeloma Read more about FDA Accepts New Drug Application for Mezigdomide in Combination with Carfilzomib and Dexamethasone as Treatment for Relapsed/Refractory Myeloma Add new comment
Sarclisa (isatuximab-irfc) Approved as a Subcutaneous Injection for Multiple Myeloma by the FDA Read more about Sarclisa (isatuximab-irfc) Approved as a Subcutaneous Injection for Multiple Myeloma by the FDAAdd new comment
CHMP-EMA Issues Positive Opinion on Teclistamab for Relapsed/Refractory Myeloma, Adopts Changes to Marketing Authorization Read more about CHMP-EMA Issues Positive Opinion on Teclistamab for Relapsed/Refractory Myeloma, Adopts Changes to Marketing Authorization Add new comment
June 2026 – Myeloma News from the Journals Read more about June 2026 – Myeloma News from the JournalsAdd new comment
Results from Phase 3 MonumenTAL-3 Study at EHA 2026: Talquetamab Plus Daratumumab Showed Significant Reduction in Risk of Disease Progression in Relapsed/Refractory Myeloma Read more about Results from Phase 3 MonumenTAL-3 Study at EHA 2026: Talquetamab Plus Daratumumab Showed Significant Reduction in Risk of Disease Progression in Relapsed/Refractory MyelomaAdd new comment
International Myeloma Foundation’s Black Swan Research Initiative Presents Data and Results of Phase 2 ASCENT Cure Trial at EHA 2026 Congress Read more about International Myeloma Foundation’s Black Swan Research Initiative Presents Data and Results of Phase 2 ASCENT Cure Trial at EHA 2026 Congress Add new comment
The Lancet Publishes Interim Analysis Data for the SUCCESSOR-2 Trial, Presented at 2026 ASCO and EHA Read more about The Lancet Publishes Interim Analysis Data for the SUCCESSOR-2 Trial, Presented at 2026 ASCO and EHA Add new comment
International Myeloma Foundation (IMF) and International Myeloma Working Group (IMWG) to Honor 2026 Kyle and Durie Achievement Awardees, Dr. Hermann Einsele and Dr. Noopur Raje Read more about International Myeloma Foundation (IMF) and International Myeloma Working Group (IMWG) to Honor 2026 Kyle and Durie Achievement Awardees, Dr. Hermann Einsele and Dr. Noopur RajeAdd new comment
